2022 Year in Pharma: A year of paradox for biotech By / On December 2, 2022 / At 1:56 pm / In Chemical world 30 Views Biotech funding woes dragged on, while employment stayed strong Post navigation Prev PostC&EN’s Year in Pharma 2022: US Supreme Court decision put medication abortions in the spotlight Next PostC&EN’s Year in Pharma 2022: Oncology, Big Pharma top out US FDA’s 2022 approvals You May Also Like Glow-in-the-dark proteins offer cheap and fast diagnostic tests On March 23, 2023 | In Chemical world Arsenite-induced necroptosis requires stress granules On March 22, 2023 | In Chemical world European response to US cleantech incentives leaves industry and environmentalists fuming On March 22, 2023 | In Chemical world